# Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

> **NCT02298647** · — · WITHDRAWN · sponsor: **CENTOGENE GmbH Rostock**

## Conditions studied

- Hepato-splenomegaly
- Dysostosis Multiplex
- Seizures
- Mental Retardation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02298647
- **Lead sponsor:** CENTOGENE GmbH Rostock
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08-20
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Transition to BioMetabol
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298647, "Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02298647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*